Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 For Prader-Willi Syndrome
Portfolio Pulse from Benzinga Newsdesk
Acadia Pharmaceuticals has announced the addition of ACP-101, a Phase 3 development candidate for the treatment of hyperphagia in Prader-Willi syndrome (PWS), to its rare disease portfolio. The company acquired worldwide rights to ACP-101 through its acquisition of Levo Therapeutics in June 2022. Acadia plans to initiate a Phase 3 study in Q4 2023.
June 13, 2023 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Acadia Pharmaceuticals adds ACP-101 to its rare disease portfolio, potentially expanding its product offerings and addressing unmet needs in central nervous system disorders.
Acadia's acquisition of ACP-101 and the worldwide rights to develop and commercialize the drug candidate demonstrates the company's commitment to addressing unmet needs in central nervous system disorders. The addition of ACP-101 to its rare disease portfolio could potentially expand Acadia's product offerings and increase its market presence. The initiation of a Phase 3 study in Q4 2023 indicates progress in the development of the drug candidate, which may positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100